GBIM - GlobeImmune, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

GlobeImmune, Inc.

1450 Infinite Drive
Louisville, CO 80027
United States
303-625-2700
http://www.globeimmune.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Mr. C. Jeffrey DekkerPres, VP of Fin., Treasurer & Sec.200.05kN/A1965
Dr. Richard C. DukeScientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Donald BellgrauScientific Founder & Chairman of The Scientific Advisory BoardN/AN/AN/A
Mr. Thomas A. KeuerActing Head of Manufacturing OperationsN/AN/A1959
Dr. Allen L. Cohn M.D.Exec. Director Clinical Devel.N/AN/A1958
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Corporate Governance

GlobeImmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.